Intranasal flunisolide treatment in patients with non-allergic rhinitis.
A Varricchio, M Capasso, A De Lucia, F Avvisati, A M Varricchio, G Bettoncelli, G Ciprandi
Index: Int. J. Immunopathol. Pharmacol. 24(2) , 401-9, (2011)
Full Text: HTML
Abstract
Non-allergic rhinitis (NAR) is a heterogeneous disease, characterized by nasal hyperreactivity and inflammation. Its treatment is still debated, intranasal corticosteroids may be an option. The present study is aimed at evaluating the effect of the use of intranasal flunisolide in patients with NAR, considering both clinical and cytological parameters. Sixty patients were treated with intranasal flunisolide (30) or saline solution (30) for 8 weeks. Symptom severity, turbinate size, and inflammatory cell counts were assessed, before and after treatment. Intranasal flunisolide induced a significant reduction of symptoms, turbinate size, and cellular infiltrate. Thus, intranasal flunisolide might be a therapeutic option for NAR.
Related Compounds
Related Articles:
2014-08-30
[Rapid Commun. Mass Spectrom. 28(16) , 1829-39, (2015)]
Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma.
2003-03-01
[Clin. Ther. 25(3) , 776-98, (2003)]
2009-01-01
[Int. J. Immunopathol. Pharmacol. 22(2) , 363-70, (2009)]
Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants.
2012-01-01
[Cochrane Database Syst. Rev. 4 , CD002311, (2012)]
Nebulized corticosteroids in asthma and COPD. An Italian appraisal.
2012-07-01
[Respir. Care 57(7) , 1161-74, (2012)]